Loading clinical trials...
Loading clinical trials...
A Single-Ascending and Repeat-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3561774
Conditions
Interventions
LY3561774
Placebo
Locations
5
United States
Altasciences Clinical Los Angeles, Inc
Cypress, California, United States
Collaborative Neuroscience Research, LLC
Long Beach, California, United States
Qps-Mra, Llc
South Miami, Florida, United States
Hassman Research Institute
Marlton, New Jersey, United States
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee, United States
Start Date
November 30, 2020
Primary Completion Date
May 17, 2022
Completion Date
May 17, 2022
Last Updated
August 10, 2022
NCT06380322
NCT07083206
NCT06568471
NCT05845424
NCT06322056
NCT06578676
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions